Roth Capital Analysts Lift Earnings Estimates for biote Corp. (NASDAQ:BTMD)

biote Corp. (NASDAQ:BTMD) – Stock analysts at Roth Capital lifted their Q4 2024 earnings per share estimates for shares of biote in a research note issued on Friday, June 21st. Roth Capital analyst G. Kelly now forecasts that the company will post earnings of $0.19 per share for the quarter, up from their previous estimate of $0.18. The consensus estimate for biote’s current full-year earnings is $0.56 per share. Roth Capital also issued estimates for biote’s Q1 2025 earnings at $0.16 EPS, Q2 2025 earnings at $0.22 EPS, Q3 2025 earnings at $0.22 EPS, Q4 2025 earnings at $0.29 EPS and FY2025 earnings at $0.88 EPS.

biote (NASDAQ:BTMD) last announced its earnings results on Tuesday, May 7th. The company reported $0.23 EPS for the quarter, topping the consensus estimate of $0.05 by $0.18. The firm had revenue of $46.80 million for the quarter, compared to the consensus estimate of $47.09 million. biote had a negative return on equity of 36.67% and a net margin of 4.30%.

Separately, Roth Mkm reissued a “buy” rating and issued a $9.00 price objective (up from $8.00) on shares of biote in a research report on Wednesday, March 13th. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company presently has a consensus rating of “Buy” and a consensus target price of $8.11.

biote Trading Down 1.6 %

BTMD stock opened at $7.23 on Monday. The stock has a 50-day moving average price of $6.17 and a 200-day moving average price of $5.50. biote has a 1-year low of $3.65 and a 1-year high of $8.22. The firm has a market cap of $448.55 million, a PE ratio of 65.73 and a beta of 0.95.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the business. SW Investment Management LLC increased its position in biote by 3.5% in the 4th quarter. SW Investment Management LLC now owns 675,000 shares of the company’s stock valued at $3,334,000 after buying an additional 22,651 shares in the last quarter. Bandera Partners LLC increased its position in biote by 7.5% in the 4th quarter. Bandera Partners LLC now owns 1,832,732 shares of the company’s stock valued at $9,054,000 after buying an additional 127,410 shares in the last quarter. Bailard Inc. bought a new stake in biote in the 4th quarter valued at about $96,000. SG Americas Securities LLC bought a new stake in biote in the 4th quarter valued at about $53,000. Finally, Kent Lake Capital LLC increased its position in biote by 0.8% in the 3rd quarter. Kent Lake Capital LLC now owns 1,284,297 shares of the company’s stock valued at $6,576,000 after buying an additional 10,596 shares in the last quarter. 21.68% of the stock is owned by institutional investors.

biote Company Profile

biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification services; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and other administrative requirements; inventory management software to monitor pellet inventory; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support.